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ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD) is a
chronic, progressive condition characterized by the develop-
ment and growth of cysts in the kidneys and other organs and
by additional systemic manifestations. Individuals with
ADPKD should have access to lifelong, multidisciplinary, spe-
cialist and patient-centred care involving: (i) a holistic and
comprehensive assessment of the manifestations, complica-
tions, prognosis and impact of the disease (in physical, psycho-
logical and social terms) on the patient and their family; (ii)
access to treatment to relieve symptoms, manage complications,
preserve kidney function, lower the risk of cardiovascular dis-
ease and maintain quality of life; and (iii) information and sup-
port to help patients and their families act as fully informed and
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active partners in care, i.e. to maintain self-management
approaches, deal with the impact of the condition and partici-
pate in decision-making regarding healthcare policies, services
and research. Building on discussions at an international round-
table of specialists and patient advocates involved in ADPKD
care, this article sets out (i) the principles for a patient-centred,
holistic approach to the organization and delivery of ADPKD
care in practice, with a focus on multispecialist collaboration
and shared-decision making, and (ii) the rationale and knowl-
edge base for a route map for ADPKD care intended to help
patients navigate the services available to them and to help
stakeholders and decision-makers take practical steps to ensure
that all patients with ADPKD can access the comprehensive
multispecialist care to which they are entitled. Further multispe-
cialty collaboration is encouraged to design and implement
these services, and to work with patient organizations to pro-
mote awareness building, education and research.
Keywords: ADPKD, CKD, clinical practice, multispecialist
care, polycystic kidney disease
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is a
chronic, progressive condition characterized by the develop-
ment and growth of cysts in the kidneys and other organs and
by additional systemic manifestations [1]. The renal cystic dis-
ease progresses throughout life, causing complications that
include pain, cyst infections, bleeding and abdominal distention
due to massive kidney enlargement. Kidney function may not
be affected for many years, owing to compensatory renal mech-
anisms. However, most patients eventually develop end-stage
renal disease (ESRD), typically before the age of 60 years, and
require renal replacement therapy (RRT) by kidney transplan-
tation or dialysis [2]. ADPKD accounts for approximately 1 in
10 of all patients needing RRT, corresponding to approximately
50 000 people across Europe [3]. Cysts also develop in the liver
in most patients [4] and occur less commonly in the seminal
vesicles, pancreas, arachnoid membrane and spinal meninges
[1]. Patients with ADPKD are at increased risk of cardiovascu-
lar and cerebrovascular complications, including hypertension,
cardiac valvular abnormalities and intracranial aneurysms [1, 5,
6]. The lifelong physical and psychological effects of ADPKD
can impair quality of life (QoL) and interfere with social
functioning and work [7–11]. These effects may be under-
appreciated by many physicians, including nephrologists, espe-
cially during the early stage of the disease [9]. Although
ADPKD is typically diagnosed in adulthood, it may present in
children (and even prenatally) and there have been calls for
greater recognition of symptomatic paediatric disease to facili-
tate early diagnosis and appropriate care [12, 13].
Approaches to ADPKD care vary between and within
European countries, with no widely accepted, evidence-based
practice guidelines. A Kidney Disease: Improving Global
Outcomes (KDIGO) initiative has begun the process toward
international guidelines by assessing the current state of knowl-
edge and best practice and proposing a research agenda [1].
National guidelines have been developed in some countries [14,
15], while European-level guidelines have been developed specifi-
cally regarding the therapeutic use of vasopressin V2 receptor
antagonists [16]. Relatively little attention has been paid to the
organization and delivery of ADPKD care and the means of over-
coming barriers to the implementation of guidelines and patient-
centred services. Practice patterns for ADPKD care are not well-
documented across Europe. Many patients may not have coordi-
nated access to the necessary range of specialists with expertise in
ADPKD and to patient-centred, multidisciplinary care. Where
specialized ADPKD centres exist, their roles, responsibilities and
added value may be unclear among nephrologists in the local
region. Patients and carers may also lack a clear understanding of
the available services and how to navigate these optimally.
In 2015, the European ADPKD Forum (EAF) published
policy-focused recommendations to help address unmet needs
among patients with ADPKD [17]. These included the develop-
ment of nationally coordinated approaches to ADPKD care and
efforts to empower patients and carers. Such approaches require
collaboration between all stakeholders. Building on discussions
at a roundtable of clinical specialists and patient advocates, con-
vened by the EAF, this article sets out (i) the principles for a
holistic, patient-centred approach to the organization and deliv-
ery of ADPKD care in practice, with a focus on multispecialist
collaboration and shared-decision making and (ii) the rationale
and knowledge base for a route map for ADPKD care.
PRINCIPLES OF ADPKD CARE: A
MULTISPECIALIST , PATIENT-CENTRED
APPROACH
Individuals with ADPKD should have access to lifelong, multi-
disciplinary, specialist and patient-centred care involving: (i) a
holistic and comprehensive assessment of the manifestations,
complications, prognosis and impact of the disease (in physical,
psychological and social terms) on the patient and their family;
(ii) access to treatment to relieve symptoms, manage complica-
tions, preserve kidney function, lower the risk of cardiovascular
disease and maintain QoL; and (iii) information and support to
help patients and their families maintain recommended self-
management approaches and to deal with the impact of the
condition [1, 17].
Patient-centred approach
We define a ‘patient-centred’ approach to ADPKD as one in
which patients and carers are empowered to act as fully informed
and active partners in decision-making regarding their care and
in healthcare policies, services and research directly or indirectly
related to the disease [17, 18]. This requires patients and carers
to have access to accurate, up-to-date information about
ADPKD, their own clinical data and the opportunity to partici-
pate in decision-making. Survey evidence suggests the provision
of written materials, and referrals to patient support groups, at
the time of diagnosis are variable and suboptimal [19]. All stake-
holders, including national governments and healthcare pro-
viders, should support efforts to better inform patients and
families and, more widely, to include patient organizations
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within strategic decision-making. Patients participated at the
KDIGOConference [1] and an expanded consultation regarding
research priorities is underway among advocacy groups (T.
Harris, personal communication). Researchers in Australia have
also elicited the perspectives of patients and carers concerning
clinical practice guidelines for ADPKD [20].
Multidisciplinary coordination
The complex and heterogeneous manifestations of ADPKD
often necessitate access to specialized services. In order to estab-
lish strategies to detect complications and prevent progression
of kidney failure, specialist care should start as soon as possible
after diagnosis, ideally when kidney function is not yet impaired
and protective measures can be taken. Some patients present
with impaired renal function and require RRT soon after diag-
nosis, while others may have a low risk of progressing to ESRD.
In all these cases, specialist care should still be considered.
All patients with ADPKD should have access to a nephrolo-
gist knowledgeable about the diverse aspects of the disease [1],
including the multi-organ involvement, psychological and psy-
chosocial issues, genetics, pain management and current treat-
ment options, in addition to the ‘core’ management of renal
function and RRT. Depending on local circumstances, referral
to an adult or paediatric nephrologist with specialist ADPKD
expertise may also be helpful in some cases for particular
aspects of care according to the evolving best practice, such as
prognostic assessment, kidney cyst infections [21, 22], specific
reno-protective pharmacotherapy [16] and for clinical trials
and other types of research. Patients should also have access to
care from a range of other clinical specialists (e.g. hepatology,
clinical genetics, neurosurgery and anaesthesiology or pain spe-
cialists) and healthcare professionals who also have specific
expertise in ADPKD, according to clinical need in the event of
other disease manifestations and complications (e.g. liver cyst
complications, intracranial aneurysms, lumbar pain; Figure 1).
They may also require treatment for other chronic diseases (e.g.
diabetes) based on a consensus among all practitioners
involved.
Howmultidisciplinary care is managed depends on the local,
regional and national organization and resourcing of services.
Where possible, a team approach with all specialties provided in
one centre would be expected to benefit expert and patient net-
working, efficiency and patient outcomes [1]. Specialist centres
also have a potential role in coordinating research efforts locally,
nationally and internationally. This is not realistic for all
patients, but most university hospitals should be able to provide
most of the services required. Where this is the case, these serv-
ices should be coordinated institutionally in a patient-centred
manner. Not all patients are routinely cared for at university
hospitals, of course, and some local nephrologists may not be
able to offer all services necessary or may not have access within
their hospital to colleagues from other specialties with appropri-
ate ADPKD expertise. In these cases, managed coordination
and networking of local, regional or national ADPKD specialist
services, based on a common understanding of the multifaceted
needs of patients and carers, is important to optimize care and
to benefit research. Informal referral pathways often exist, but
we argue that services should ideally be formally organized
according to predefined pathways. Such coordination requires a
consensus involving all practitioners, patients and providers.
To our knowledge, the relative cost-effectiveness of different
delivery models of multidisciplinary ADPKD care have not
been compared. Ongoing evaluation of the cost–benefit of care
models is important, taking account of the ‘downstream’
increase in healthcare costs that occurs in later life among
patients who require dialysis [23, 24]. However, managed
coordination would be expected to facilitate prompt, accurate
diagnosis, avoidance of duplication of tests, better management
FIGURE 1: Schematic overview of key specialties involved in care for ADPKD showing examples of indications that may warrant referral
subject to individual circumstances and local care organization.
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of disease complications and manifestations, and evidence-
based access to specific reno-protective treatment, and ulti-
mately to improve patient outcomes.
New technologies could facilitate interdisciplinary network-
ing and research, and promote patient empowerment and self-
care. These include telecommunication and information tech-
nologies (‘telemedicine’ or ‘telenephrology’) that allow online
consultation and videoconferencing, data and image sharing,
education and biomarker development. Such modalities could
have a particular role in supporting consultation between local
nephrology services and distant specialist centres on specific
aspects of care and research, reducing the need for patients to
travel to the latter. These measures will be facilitated by the
recent implementation of the European Rare Kidney Disease
Reference Network (ERKNet), which aims to improve stand-
ards of diagnosis and treatment for rare and complex kidney
diseases [25]. Polycystic liver disease will also be covered within
the European Reference Network (ERN) on Hepatological
Diseases (ERN RARE-LIVER) [26].
Patients’ access to information also underpins their participa-
tion in shared decision-making. Regular monitoring may be
important for some patients to improve their understanding and
sense of control, to facilitate self-management and to allow them
to prepare for RRT [20]. For example, the Renal PatientView
system in the UK (https://www.patientview.org/#/; 15 November
2017, date last accessed) provides patients with web-based access
to laboratory results and educational material [27, 28].
ADPKD ROUTE MAP: CONCEPT AND AIMS
Route maps provide ‘signposts’ to health and social care
for patients and their families in order to improve their
access to information and to facilitate earlier diagnosis and
improved care and support. Route maps can also help health
and social care professionals to communicate, and work in
partnership, with patients and families. Examples of route
maps include those for arthritis [29] and spinal muscular
atrophy [30].
An ADPKD Patient Route Map is in development to pro-
mote good practice in lifetime ADPKD care among all stake-
holders. Specifically, the Route Map aims to:
• Inform patients and families about what they can expect
from a good-quality service, engaging and supporting
them to take a partnership role in their own care, thereby
improving the dialogue between patients and physicians
and helping patients to navigate available services
• Assist patient organizations in participating in the
decision-making regarding the design, implementation
and assessment of ADPKD services
• Support healthcare providers and policymakers to design,
adapt or assess coordinated services to efﬁciently address
current unmet needs and to take advantage of develop-
ments in knowledge, therapy and technology, taking into
account local healthcare system conditions
The Route Map is being developed collaboratively by the
EAF and PKD International, with input from member patient
organizations across Europe. It is not a clinical practice guide-
line and is not intended to be prescriptive, nor a complete solu-
tion appropriate for all settings. Rather, it is intended to offer a
practical, flexible, interactive and adaptable model that integra-
tes, translates and stages key elements of good practice for
patients and other stakeholders, according to the principles
defined above and based on the latest knowledge base and good
practice. It will be published as an open-access resource on the
PKD International website for use and local adaptation by all
stakeholders (e.g. patients, families, healthcare professionals
and policymakers).
The Route Map is presented in terms of key assessments and
interventions at distinct stages, together with considerations
that apply to the different stages of the disease throughout a
patient’s lifetime (Figure 2). The following sections overview
FIGURE 2: Schematic illustration of a template patient Route Map for ADPKD care.
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the main domains, highlighting key unmet needs and barriers
and focusing on opportunities for inter-specialist co-operation
for non-renal manifestations and complications.
SCREENING AND DIAGNOSIS
A diagnosis of ADPKD can have important lifelong effects on
patients, including psychosocial and financial consequences. The
advantages and disadvantages of offering screening to a patient’s
family members should be carefully discussed. The offer of
screening should be provided with appropriate counselling on the
implications of a diagnosis for adults and children. Routine pre-
symptomatic screening of ADPKD is not recommended for at-
risk children, while it is usually thought that the benefits outweigh
the risks in adults [1]. Ultrasound imaging is recommended for
parents of children or adolescents in whom ADPKD is suspected
and who have no previous family history of ADPKD [13].
ADPKD is diagnosed in adults and children mainly by ultra-
sound imaging [1]. Magnetic resonance imaging (MRI) may be
useful to confirm or exclude the diagnosis. Both can be used for
prognostic assessment. Specialist consultation is recommended
for paediatric patients with renal cysts, as genetic testing is often
required to confirm the diagnosis when clinical findings are
equivocal [1, 13]. A detailed examination and additional inves-
tigations should be performed to identify extra-renal manifesta-
tions if appropriate.
BLOOD PRESSURE CONTROL, LIFESTYLE
AND SELF-CARE
Control of hypertension and other cardiovascular risk factors is a
key aspect of early ADPKDmanagement [1]. Cardiovascular dis-
ease is the leading cause of premature death in people with
ADPKD [3] and yet risk management may be sub-optimal [31].
Up to 20% of paediatric patients with ADPKD may have hyper-
tension [32]. In children and adults, 24-h ambulatory blood pres-
sure monitoring can be helpful to detect prehypertension and any
diminution of the normal fall in overnight blood pressure [1, 13].
Patients should be provided with comprehensive, up-to-date
written information on recommended lifestyle and self-care
aspects (Table 1). Although evidence specifically in ADPKD is
lacking, patients should be advised on the expected antihyperten-
sive benefits of lifestyle adaptation, such as weight control, exer-
cise and a low-salt diet. There is no good evidence that protein-
limited diets slow the progression of ADPKD [33]. Others have
advised a moderate protein intake (0.75–1.0 g/kg/day) for adults
with ADPKD, commensurate with that in the general population
[34]. KDIGO guidelines for general chronic kidney disease
(CKD) care in adults recommendmoderate protein limitation (to
0.8 g/kg/day) when estimated glomerular filtration rate (eGFR)
is<30mL/min/1.73 m2, along with the avoidance of high protein
intake (>1.3 g/kg/day) in those at risk of CKD progression [35].
Where protein restriction is applied, it should preferably involve
education by a renal dietician and monitoring for malnutrition,
especially those patients with high total kidney and liver volumes
whose nutritional intake may become insufficient. A recent
Cochrane review has drawn attention to the limitations in the evi-
dence base for dietary interventions for adults with CKD [36].
Peer-to-peer support from patient organizations may aid
adherence to lifestyle and diet measures, together with regular
reinforcement by healthcare practitioners.
Angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers are the first-line antihypertensives in
ADPKD. The KDIGO CKD blood pressure target of 140/90
mmHg is recommended for individualized use, taking
comorbidities into account [1]. Data from the HALT PKD
study suggest that a lower target might benefit young hyperten-
sive ADPKD patients (15–49 years) at CKD Stages 1 or 2 and
without diabetes mellitus or significant cardiovascular comor-
bidities [37]. In this group, a target of 95/60–110/75 mmHg was
associated with a slower increase in total kidney volume (TKV),
though no overall change in the eGFR, together with a greater
decline in the left-ventricular-mass index and a greater reduc-
tion in urinary albumin excretion, as compared with a target of
120/70–130/80 mmHg [37]. A cardiology referral is needed if
signs or symptoms of cardiac disease are evident.
LIVER CYSTS
Liver cysts are the most common extra-renal manifestation of
ADPKD and a recent case series suggested that biliary disease is
Table 1. Information for patients, carers and families affected by autosomal dominant polycystic kidney disease (ADPKD)
Disease information Explanation of the disease and its potential course and manifestations
Details of ADPKD patient organizations
Basic management and self-care Self-management: water intake, low-salt diet, low-protein diet (where appropriate),
weight control, lifestyle (e.g. exercise), smoking cessation, caffeine intake
Cardiovascular risk management: importance, antihypertensive therapy, cholesterol-lowering therapy
Situations for contacting clinic (e.g. pain, complications)
Prognostic assessment Rationale, interpretation and implications of prognostic risk score
Speciﬁc reno-protective pharmacotherapy Indication, rationale/beneﬁt, adverse effects, monitoring requirements
Clinical trial opportunities
Managing disease impact Potential impact of the disease on activity (e.g. work and lifestyle)
Psychological impact and support available
Discussing ADPKD with employers
Issues regarding health insurance and mortgage applications
Family planning, including genetic counselling and pre-implantation genetic
diagnosis, contraception and pregnancy issues
Renal replacement therapy Dialysis and transplantation options (according to clinical situation and availability)
Research Registry entry, clinical trials, patient-reported outcome data collection
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also a frequent complication in ADPKD [38]. Liver cysts can
occur at any disease stage (irrespective of marked progression
of CKD) and affect women in particular. Liver cysts can con-
tribute significantly to pain, gastrointestinal symptoms and
QoL impairment [4, 11, 39–41]. All patients with ADPKD
should be assessed for polycystic liver disease, and those with
liver cyst complications should be referred to a hepatologist as
necessary. Liver symptoms can be assessed using the polycystic
liver disease questionnaire (PLD-Q) [40]. Current guidelines
suggest that patients with moderate-to-severe polycystic liver
disease should avoid oestrogens [42], in view of the evidence
that exogenous oestrogen increases liver (but not renal) volume
in postmenopausal ADPKD patients [43].
INTRACRANIAL ANEURYSMS
Intracranial aneurysms are an uncommon but important mani-
festation of particular concern to patients. One survey in
patients with ADPKD found a self-reported prevalence rate of
5.0% for brain aneurysm and 7.5% for stroke or cerebral bleed-
ing [6]. A recent systematic review reported that unruptured
intracranial aneurysms occur in around 11% of patients with
ADPKD [44], as compared with around 3% in the general pop-
ulation [45]. The rate of rupture among patients with ADPKD
appears similar to that in the general population: a rupture rate
of 0.4%/patient-year was reported among ADPKD patients
with conservatively treated aneurysms [44]. In the general pop-
ulation, the rupture rate depends strongly on the size and loca-
tion of the aneurysm.
Systematic screening for intracranial aneurysms is not rec-
ommended for all patients with ADPKD, but is recommended
in certain groups at elevated risk [1, 46]. Consultation with a
neurosurgeon and neurovascular radiologist is needed in the
management of identified aneurysms [1, 5, 46].
PAIN
Pain is a principal symptom of ADPKD. Even in early disease
stages, patients can experience acute or chronic pain that can
interfere with daily activities and cause distress [7, 9, 47].
ADPKD-specific causes of pain include kidney and liver cyst
haemorrhage and infection and urinary stones. Pain may be
under-assessed in the clinic and under-recognized by physi-
cians, leading to inadequate management and feelings of
powerlessness among patients [9, 20, 47].
Physicians should carefully ascertain and assess patients’
pain at each clinic visit and discuss management options
according to current best practice. Chronic pain in ADPKD is
often refractory, and may necessitate referral, e.g. involving
radiologists, physical therapists and pain specialists [1]. A mul-
tidisciplinary, stepwise protocol in the Netherlands has recently
shown promising results [48].
PSYCHOSOCIAL SUPPORT
ADPKD can significantly impair QoL and psychosocial well-
being, and can be associated with depression and anxiety [9, 10,
11, 49]. Typical issues include worry and fear (associated, for
example with pain, unpredictability of symptoms, the effect of
the disease on work and finances, future need for dialysis or the
diagnosis of intracranial aneurysm), confusion (which might be
linked with a lack of correct information), as well as anger and
guilt.
Physicians should recognize the potential psychological,
social and functional effects of ADPKD at all disease stages.
Measurement of patient-reported outcomes, such as health-
related QoL, is important. ADPKD-specific instruments are
more sensitive than generic ones, especially in early disease.
Recently developed disease-specific tools include the ADPKD
Genetic Psychosocial Risk Instrument (GPRI-ADPKD) [10]
and the ADPKD Impact Scale (ADPKD-IS) [50], along with
the aforementioned PLD-Q [40]. Ideally, patient-reported out-
comes should be measured routinely during consultations,
although further research is required to define clinically signifi-
cant changes in scores. The UK Renal Registry is evaluating
routine QoL data collection within its Transforming
Participation in Chronic Kidney Disease initiative, which aims
to help patients manage their own condition and plan future
services [51]. The collection of patient-reported outcomes is
also a potential role for reference networks at national and
European levels.
Patients and carers should have access to psychological and
social support services, according to need. Patients and carers
should also receive information on managing the impact of
ADPKD on employment, mortgages and other financial
aspects, and health insurance. Patient organizations play an
important role in this respect. Other relevant educational topics
for patients and parents include contraception, pregnancy and
medication adverse effects [1, 20]. The role of complementary
medicines is a topic of interest to some patients [20] and on
which nephrologists and other healthcare professionals may
need to offer advice. There is no evidence that any complemen-
tary or alternative therapy helps to protect the kidneys or to
slow the progression of ADPKD. Patients should be encouraged
to ask their doctor before using any complementary therapy
and should never stop a treatment prescribed by a doctor on
the advice of a complementary practitioner without discussing
it with their doctor.
PROGNOSTIC ASSESSMENT
Progression risk scoring
Prognostic assessment during the early stages of ADPKD
has become increasingly important to identify patients with
rapidly progressing disease who may be eligible for new reno-
protective therapies or clinical trials [1, 16, 52]. It warrants asso-
ciated investment, awareness building and training and support
by healthcare policymakers and providers [17].
The height-adjusted TKV is the gold-standard image bio-
marker for early ADPKD progression [53]. Classical volumetry
to measure TKV from MRI images is laborious and expensive
and may not be viewed as an efficient use of time by some radi-
ologists. New, automated methods should allow faster, less
labour-intensive imaging at lower costs and thereby facilitate
repeat TKV measurement in routine practice [54, 55]. In addi-
tion, estimating TKV using MRI images and the ellipsoid
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equation is an easy to use and quick surrogate for classical TKV
measurement, and seems to perform sufficiently well to be used
in clinical practice [56]. Improving the uptake and implementa-
tion of suchmethods, and access to repeat MRI imaging, should
be a target for collaboration between nephrologists and radiol-
ogists. An image classification of ADPKD based on height-
adjusted TKV and age has been proposed to optimize patient
selection for enrolment into clinical trials or treatment [57].
Other approaches to prognostic risk scoring include the
PROPKD score, which predicts the risk of progression to ESRD
using four factors: gender, presence of hypertension before 35
years of age, first urologic event before 35 years of age and geno-
type [58]. A recent study has demonstrated the prognostic value
of fasting urine osmolality (Uosm) to predict disease progres-
sion and response to treatment in ADPKD [59]. Determination
of Uosm is non-invasive, affordable and valued as an integrative
marker of renal function that could improve or complement
the existing scores to predict renal outcome in patients with
ADPKD.
Genetic testing
Although diagnostic genetic testing for ADPKD mutations
is not required for most patients, it can be important where
clinical findings are equivocal or atypical, especially in children
[1, 13]. Where possible, patients should have access to testing
via clinical geneticists with ADPKD expertise. Access to genetic
testing varies across Europe with key barriers including the cost
of tests, resourcing of services, diverse reimbursement policies
and a lack of clear, reliable information in some countries.
Although data are lacking, the European Expert Group on Rare
Diseases (EUCERD) have observed that genetic testing may
offer economic advantages by avoiding unnecessary diagnostic
and therapeutic procedures [60]. Next-generation sequencing
technologies offer increasingly cost-efficient diagnostic strat-
egies [61]. The ERKNet aims to develop standard criteria
for genetic testing for inherited rare and complex kidney
diseases [25].
Patients should have access to family planning services,
including pre-implantation genetic diagnosis (PGD). PGD is
used in reproductive medicine to screen for DNA mutations
that cause inherited diseases in embryos created by in vitro fer-
tilization. Anecdotally, PGD is of interest within the ADPKD
patient community (T. Harris, personal communication). A
UK survey suggested that many patients with ADPKD would
seek PGD if it were available and that a majority believed it
should be offered [62]. Currently, access to PGD varies for rea-
sons that include regulatory, ethical and legal policies, cost,
reimbursement policies, and attitudes among doctors and soci-
ety [63]. Regarding cost issues, the potential for significant soci-
etal cost savings by avoiding ADPKD cases should be
considered [1], although data are lacking. Other barriers may
include low awareness of the method among patients.
Nephrologists, geneticists and patient organizations have roles
in collaboratively advocating for governments to formulate
national polices on PGD.
All forms of genetic testing must be accompanied by access
to accurate, personalized information and to counselling, pref-
erably by clinical geneticists with ADPKD expertise [1, 13, 63].
SPECIFIC RENO-PROTECTIVE
PHARMACOTHERAPY
In Europe, a vasopressin V2 receptor antagonist (tolvaptan) is
indicated to slow the progression of cyst development and renal
insufficiency in ADPKD in adults with CKD Stage 1–3 at initia-
tion of treatment with evidence of rapidly progressing disease
[64]. European experts have published a decision algorithm to
assess whether treatment is warranted, taking into account the
adverse event profile and costs of treatment [14]. This guidance
is expected to also help set the indications for other future
therapies. Currently, patients’ access to treatment, and its
deployment within nephrology services, varies across Europe
and national guidelines have been developed in some countries
[65, 66]. Shared decision-making with patients is advocated:
issues to be discussed with patients include the mechanism of
drug action, expected adverse events, and need for precautions
and lifestyle modifications [16]. Due to its mode of action, tol-
vaptan causes class effects of thirst, polydipsia, dry mouth, noc-
turia, pollakisuria and polyuria. Patients must be counselled to
avoid dehydration [64]. In the TEMPO 3:4 trial, idiosyncratic
increases [>3 the upper limit of normal (ULN)] in alanine
transaminase (ALT) and aspartate transaminase (AST) were
observed in 4.4% and 3.1% of tolvaptan-treated patients, respec-
tively, compared with 1.0% and 0.8% of placebo recipients. Two
(0.2%) tolvaptan treated-patients, and a third patient treated in
the TEMPO 4:4 extension trial, showed increases in hepatic
enzymes (>3ULN) with concomitant elevations in total bilir-
ubin (>2 ULN) [64, 67]. Blood testing for transaminases and
bilirubin is therefore required prior to initiation of tolvaptan,
continuing monthly for 18months and at regular 3-monthly
intervals thereafter [64].
Other novel pharmacological approaches to slowing
ADPKD progression are currently under investigation [52].
FOLLOW-UP CARE
Life-long follow-up care for patients with ADPKD requires
coordination between nephrologists (locally and at specialist
centres, where relevant), other secondary care specialists and
primary care physicians. Patients referred to specialist centres
for particular assessments or interventions would typically be
expected to return to the care of their local nephrologist for
ongoing care, pending the need for any further consultation.
The frequency of scheduled nephrology follow-up visits
depends on CKD stage, blood pressure, specific monitoring
requirements (e.g. associated with specific reno-protective ther-
apy), complications and other clinical factors. An annual
follow-up for adults without renal failure and with controlled
blood pressure has been recommended [14, 52].
Primary care physicians may see relatively few patients with
ADPKD but should be alert to the impact that the condition
can have throughout its course and to current approaches to
treatment, monitoring and support. Patients with suspected
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ADPKD should be referred to a nephrologist, at least for a first
visit, to establish the diagnosis, assess the rate of progression
and the potential indication for specific reno-protective treat-
ment, and to evaluate the presence of possible complications.
Re-referral procedures should be established according to clini-
cal need and the evolving standards of good practice.
For example, nephrology re-referral has been recommended
in the event of complications or if eGFR falls below 60 mL/min
[52]. Patients should be clearly informed regarding the roles of
the healthcare professionals and appropriate contact proce-
dures and actions if they experience complications. Special con-
siderations for paediatric patients include the coordination of
transitional care between paediatric and adult specialist
nephrologists.
ESRD
Dialysis and transplantation
Kidney transplantation is the optimal RRT modality [1, 68],
resulting in excellent patient and graft survival, improved QoL and
lower healthcare costs compared with dialysis [3, 69–71]. Patients
with ESRD due to ADPKD should be offered the opportunity to
join a kidney transplant waiting list, if no contraindications exist.
Pre-emptive transplantation from a living donor gives the best out-
comes [68, 72], and this is facilitated in ADPKD by the relatively
predictable decline in renal function. Pre-transplant nephrectomy
is not routinely performed, but may be appropriate in selected
individuals [1, 68]. Patients with symptomatic massive polycystic
liver disease may be evaluated for isolated liver transplant or com-
bined liver and kidney transplant, depending on kidney function.
Importantly, even after a successful kidney transplant, patients
require ongoing monitoring, care and support with respect to
non-renal manifestations and complications.
Across Europe, fewer than 1 in 10 patients with ADPKD
undergo kidney transplant as their first mode of RRT. Around
7 out of 10 of these transplants come from living donors [2].
Rates of kidney transplantation overall, and living donation,
vary considerably between countries. In the Netherlands, 52%
of all kidney transplants in 2015 came from living donors, while
in some European countries this figure was <10% [73]. The
autosomal dominant nature of ADPKD necessitates screening
of potential related donors to exclude the disease. However, this
need not be an obstacle to living donation: across Europe, the
proportion of patients with ADPKD who receive a living donor
kidney transplant as their first mode of RRT is more than twice
as high as that in non-ADPKD CKD [2]. The main limitation is
a shortage of available kidneys, while other barriers result from
infrastructure, funding, legal frameworks, and attitudes among
physicians and the public. Collaborative efforts are needed to
improve access to transplantation in line with EU initiatives. In
March 2016, the European Commission Working Group on
Living Donation published a Toolbox to help Member States
establish or optimize living donor programmes [74].
Haemodialysis and peritoneal dialysis are both suitable for
most patients with ADPKD who cannot undergo a transplant
or who are awaiting a transplant, and the choice between them
should be made according to the individual circumstances [1].
Peritoneal dialysis is often not considered for use in patients
with ADPKD owing to a lack of knowledge or experience of its
use in this indication. However, it can be an adequate mode of
RRT in most ADPKD patients [75–77]. Nephrologists and
patients should therefore be fully informed on the potential use,
and limitations, of this modality in ADPKD.
Evidence suggests that there is room for improvement in the
information on RRT options provided to patients with all forms
of CKD, and in the involvement of patients in decision-making
[78, 79]. A European Commission-funded study, titled the
‘Effect of Differing Kidney Disease Treatment Modalities and
Organ Donation and Transplantation Practices on Health
Expenditure and Patient Outcomes’ (EDITH) pilot study is
underway to assess the different treatment modalities for CKD
in Europe and the factors influencing the treatment choices
[80]. This study also aims to further develop and establish regis-
tries to follow-up living donors and transplant recipients.
RESEARCH
Further research is needed to improve our understanding of
ADPKD and to improve patient outcomes [1, 20]. Patients
should be informed of opportunities to join registries and clini-
cal trials. Paediatric patients with ADPKD should be included
in research projects, as early disease detection and application
of novel therapies at early disease stages might significantly
improve the long-term outcome.
Local or national ADPKD registries provide valuable data,
but these exist only in few European countries. Further, interna-
tional, multispecialist collaboration is necessary to address the
challenges of ADPKD research [17]. The ERKNet and ERN
RARE-LIVER are valuable developments in this regard.
CARE QUALITY CHECKLISTS
No widely accepted care quality standards exist for ADPKD,
reflecting the lack of international evidence-based guidelines
and pathways. The KDIGO Conference recommended that
consultation checklists are needed for both patients and physi-
cians and that these should include the patient’s experience of
care and the impact of the disease, as well as the management of
renal and extra-renal complications. A Quality Improvement
Tool, comprising checklists at each Route Map stage, is being
developed in conjunction with patients to help them, and other
stakeholders, assess care quality.
CONCLUSIONS
While healthcare delivery is the responsibility of national govern-
ments and providers, European-level bodies have an important
role in fostering greater harmony in the approach to ADPKD.
Individuals with ADPKD should have access to coordinated,
patient-centred, multispecialist care according to the principles
defined herein. Collaboration between the various specialists
involved in ADPKD care is encouraged to design and implement
these services, and to work with patient organizations to promote
awareness building, education and research. All stakeholders,
including national governments and healthcare providers,
should support efforts to better inform patients and families and
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to empower them to act as fully informed and active partners in
care, i.e. to maintain self-management approaches, deal with the
impact of the condition, and participate in decision-making
regarding healthcare policies, services and research. The
ADPKD Route Map, developed collaboratively by multidiscipli-
nary ADPKD experts and patients, is a new tool to help patients
navigate the services available to them and to help stakeholders
and decision-makers take practical steps to ensure that all
patients with ADPKD can access the comprehensive multispe-
cialist care to which they are entitled.
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